APTO News and Press, Aptose Biosciences Inc. From 05/02/22

SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan...

SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter en...

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) traded today at $9.45, eclipsing its 52-week high. This new high was reached on above average trading volume as 101.8 million shares traded hands, while the average 30-day volume is approximately 429,000 shares. Aptose Biosciences Inc is a ...

─ Appoints Philippe Ledru as Chief Commercial Officer ─ ─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─ SAN DIEGO and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company&#x...

SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malign...

Aptose Biosciences (APTO -5.9%) stock declined following its Q4 and full year 2021 results. Full year 2021 net loss widened to -$65.35M, compared to net loss of -$55.24M in 2020. The company said the increased net loss was due to $12.5M in license fees paid to Hanmi for development rights of ...

GAN (GAN) -18% on Q4 earnings release. Aptose Biosciences (APTO) -13% on Q4 earnings release. JX Luxventure (LLL) -11%. Yumanity Therapeutics (YMTX) -11%. Hyzon Motors (HYZN) -10% on Q4 earnings release. Troika Media Group (TRKA) -10%. Poshmark (POSH)&#...

Aptose Biosciences Inc. (APTO) Q4 2021 Results Conference Call March 22, 2022 05:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and IR Dr. William G. Rice - Chairman, President and CEO Dr. Joti Marango - SVP, CFO, and Chief Business Officer Dr. Rafael Bejar - SVP a...

Aptose Biosciences press release (NASDAQ:APTO): Q4 GAAP EPS of -$0.27 misses by $0.11. Total cash and cash equivalents and investments as of December 31, 2021 were $79.1 million. Cash runway into fourth quarter of 2023. Shares -8.59%. For further details see: Aptose Biosciences GAAP EPS...

- HM43239 clinical remission at 120mg expands list of potential treatable AML populations - - On track to initiate genotype-enriched expansion program for HM43239 in 2H22 - - Cash runway into fourth quarter of 2023 - - Conference call and webcast at 5:00 pm ET to...